Volunteer for a Study

"Through research, you can make a difference."

ResearchMatch is a national registry that brings together researchers and people who are interested in participating in research studies.

Signing up is free and anyone can join. To learn more about the registry, visit ResearchMatch.org.

Blood donors

Dr. Christine McDonald's laboratory is in need of blood donors. Donors will be monetarily compensated for up to 8 ounces (240 cc) of blood.

If interested, please contact Dr. McDonald by phone (445-7058) or email mcdonac2@ccf.org. A signed consent form is required.

Diet, Exercise and Body Fat studies

Obesity is a leading global health problem and is linked to multiple chronic diseases including insulin resistance, type 2 diabetes, liver disease, heart disease, stroke and certain types of cancer. In the Kirwan lab, we are focused on developing exercise and dietary interventions, and medical devices that can most effectively reverse many of these chronic diseases.

If you are overweight, a non-smoker and aged between 18 and 70, you may be eligible for one of our current studies. For more information on our active studies and how to get involved just go to the participate tab on our website: http://www.lerner.ccf.org/pathobio/labs/kirwan/

Asthma and Pulmonary Arterial Hypertension Studies

To find detailed study information and to request more information on Dr. Erzurum's studies, search "asthma" on TrialX.

Asthma Clinical Trials

One of the most common chronic diseases in the world, asthma has become more prevalent and more severe in recent years. While genetic and environmental factors, such as virus infections and allergen or occupational exposures, contribute to its origins and progression, chronic airway inflammation is considered the underlying cause of the hyper-responsiveness to environmental triggers and the airway structural changes that occur in patients over time.

Pathobiology of Asthma

A talented multidisciplinary team of investigators at the Cleveland Clinic received this NIH-sponsored study to identify the causes of asthma inflammation.

Inclusion criteria: Asthma; informed consent.
For more information, contact: Michelle Koo 216.445.1756

Severe Asthma Research Program (SARP)

The National Institutes of Health have funded a multicenter research study to learn more about severe asthma. Individuals with severe asthma make up ten percent of the asthmatic population but use the majority of health care services when compared to other asthmatics. The Cleveland Clinic and other respiratory centers have been asked to participate. The information gained from this study will be used to learn more about the causes, treatments, and disease process of severe asthma and hopefully increase the quality of life for the patients suffering from this disorder.

Inclusion criteria: Asthma; informed consent.
For more information, contact: Emmea Clegget-Mattox 216.445.1756

Pulmonary Arterial Hypertension Studies

Pulmonary arterial hypertension (PAH) is a life-threatening disease of unknown etiology characterized by a progressive increase in pulmonary artery pressure and vascular remodeling. Secondary forms of PAH are associated with known diseases, such as collagen vascular diseases or portal hypertension, but in the absence of an identifiable etiology are classified as idiopathic (IPAH). Abnormalities in vasodilators, specifically nitric oxide (NO), and mitochondrial abnormalities have been implicated in the pathogenesis of IPAH. The mechanisms for NO deficiency are complex, but inflammation and consequent oxidative stress contribute to the consumption of NO, and ultimately to the pathobiology of PAH. The Cleveland Clinic is studying mechanisms of vascular remodeling and abnormalities of metabolism through grants from the Cardiovascular Medical Research Education Fund and the National Institutes of Health.

Currently, there is an ongoing study investigating the effects of the Beta-Blocker Carvedilol (FDA Approved) on the Right Heart in PAH Patients. This 6 month long study consists of 7 visits. We hypothesize that use of Carvedilol in patients with PAH will reverse molecular markers, improve right and left ventricular function, decrease right and left ventricular size, and improve exercise and functional capacity.  For more information and enrollment please call or e-mail:

Emir Charles Roach- Study Coordinator
216-445-7706
roache@ccf.org